On this page

Fluocinonide

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Fluocinonide
Generic name
Fluocinonide
Dosage form
Solution
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
16
Packages
23
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Fluocinonide .5 mg/mL 310364 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Topical
Presentations
39

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
209699
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 29, 2018
Sponsor
ENCUBE ETHICALS
Products on application
1
Submissions recorded
1
Products approved under application 209699.
Product Trade name Form Strength Ingredient Status TE Flags
209699-001 FLUOCINONIDE SOLUTION FLUOCINONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 209699.
Type No. Action Status Date Review
Original application 1 Approved November 29, 2018 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260320). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260320 HUMAN PRESCRIPTION DRUG · 20250801 HUMAN PRESCRIPTION DRUG · 20250701 HUMAN PRESCRIPTION DRUG · 20221004

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Fluocinonide Topical Solution USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Fluocinonide Topical Solution USP, 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis Maceration of the skin Secondary infection Skin atrophy Striae Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Quagen Pharmaceuticals LLC. at 1-888-344-9603 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions.

Description

openFDA Drug Labeling

DESCRIPTION Fluocinonide topical solution USP, 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4 -diene-3,20 -dione,21-(acetyloxy)-6 ,9 -difluoro -11-hydro xy-16 ,17-[(1- methylethylidene)bis(oxy)]-,(6 α, 11β, 16 α)-. It has the following chemical structure: Fluocinonide, USP is white or almost white microcrystalline powder. It is practically insoluble in water, very slightly soluble in ether, slightly soluble in ethanol, methanol and dioxane, sparingly soluble in acetone and chloroform. Fluocinonide topical solution USP, 0.05% contains fluocinonide USP, 0.5 mg/mL in a solution of citric acid monohydrate, dehydrated alcohol (35%), diisopropyl adipate, propylene glycol and purified water. In this formulation, the active ingredient is totally in solution. Fluocinonide topical solution USP, 0.5%

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS .) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-886-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Fluocinonide Topical Solution USP, 0.05% is clear solution free from particulate matter and is supplied as: NDC 70710-1284-8 in bottle of 20 mL NDC 70710-1284-3 in bottle of 60 mL Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat, above 40°C (104°F). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please address medical inquiries to, (MedicalAffairs@zydususa.com) Tel.: 1-877-993-8779.

Adverse event reports

Source: openFDA FAERS
5,595
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLUOCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-9583-1 63629-9583 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (63629-9583-1) / 60 mL in 1 BOTTLE December 12, 2022
72162-1270-6 72162-1270 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-1270-6) / 60 mL in 1 BOTTLE April 19, 2019
72162-2146-6 72162-2146 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-2146-6) / 60 mL in 1 BOTTLE February 27, 1995
72162-2490-2 72162-2490 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-2490-2) / 20 mL in 1 BOTTLE May 14, 2025
72162-2490-6 72162-2490 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-2490-6) / 60 mL in 1 BOTTLE May 14, 2025
0168-0134-60 0168-0134 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 1 BOTTLE in 1 CARTON (0168-0134-60) / 60 mL in 1 BOTTLE February 27, 1995
21922-001-01 21922-001 Encube Ethicals, Inc. 1 BOTTLE in 1 CARTON (21922-001-01) / 60 mL in 1 BOTTLE April 19, 2019
43386-026-02 43386-026 Lupin Pharmaceuticals,Inc. 1 BOTTLE in 1 CARTON (43386-026-02) / 20 mL in 1 BOTTLE July 21, 2017
43386-026-06 43386-026 Lupin Pharmaceuticals,Inc. 1 BOTTLE in 1 CARTON (43386-026-06) / 60 mL in 1 BOTTLE July 21, 2017
33342-320-84 33342-320 Macleods Pharmaceuticals Limited 1 BOTTLE in 1 CARTON (33342-320-84) / 20 mL in 1 BOTTLE April 24, 2018
33342-320-85 33342-320 Macleods Pharmaceuticals Limited 1 BOTTLE in 1 CARTON (33342-320-85) / 60 mL in 1 BOTTLE April 24, 2018
72603-703-01 72603-703 NorthStar RxLLC 1 BOTTLE in 1 CARTON (72603-703-01) / 60 mL in 1 BOTTLE July 1, 2025
40032-026-06 40032-026 Novel Laboratories, Inc. 1 BOTTLE in 1 CARTON (40032-026-06) / 60 mL in 1 BOTTLE July 21, 2017
68071-3918-6 68071-3918 NuCare Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (68071-3918-6) / 60 mL in 1 BOTTLE November 26, 2025
70752-154-05 70752-154 QUAGEN PHARMACEUTICALS LLC 1 BOTTLE in 1 CARTON (70752-154-05) / 60 mL in 1 BOTTLE March 15, 2025
71656-094-20 71656-094 Saptalis Pharmaceuticals, LLC. 20 mL in 1 BOTTLE (71656-094-20) May 11, 2026
71656-094-60 71656-094 Saptalis Pharmaceuticals, LLC. 60 mL in 1 BOTTLE (71656-094-60) May 11, 2026
51672-1273-2 51672-1273 Sun Pharmaceutical Industries, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (51672-1273-2) / 20 mL in 1 BOTTLE, PLASTIC December 31, 1996
51672-1273-4 51672-1273 Sun Pharmaceutical Industries, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (51672-1273-4) / 60 mL in 1 BOTTLE, PLASTIC December 31, 1996
70771-1375-3 70771-1375 Zydus Lifesciences Limited 60 mL in 1 BOTTLE (70771-1375-3) November 1, 2018
70771-1375-8 70771-1375 Zydus Lifesciences Limited 20 mL in 1 BOTTLE (70771-1375-8) November 1, 2018
70710-1284-3 70710-1284 Zydus Pharmaceuticals USA Inc. 60 mL in 1 BOTTLE (70710-1284-3) November 1, 2018
70710-1284-8 70710-1284 Zydus Pharmaceuticals USA Inc. 20 mL in 1 BOTTLE (70710-1284-8) November 1, 2018
63629-9583 63629-9583 Bryant Ranch Prepack — April 19, 2019
72162-1270 72162-1270 Bryant Ranch Prepack — April 19, 2019
72162-2146 72162-2146 Bryant Ranch Prepack — February 27, 1995
72162-2490 72162-2490 Bryant Ranch Prepack — May 14, 2025
0168-0134 0168-0134 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC — February 27, 1995
21922-001 21922-001 Encube Ethicals, Inc. — April 19, 2019
43386-026 43386-026 Lupin Pharmaceuticals,Inc. — July 21, 2017
33342-320 33342-320 Macleods Pharmaceuticals Limited — April 24, 2018
72603-703 72603-703 NorthStar RxLLC — July 1, 2025
40032-026 40032-026 Novel Laboratories, Inc. — July 21, 2017
68071-3918 68071-3918 NuCare Pharmaceuticals, Inc. — April 19, 2019
70752-154 70752-154 QUAGEN PHARMACEUTICALS LLC — March 15, 2025
71656-094 71656-094 Saptalis Pharmaceuticals, LLC. — May 11, 2026
51672-1273 51672-1273 Sun Pharmaceutical Industries, Inc. — December 31, 1996
70771-1375 70771-1375 Zydus Lifesciences Limited — November 1, 2018
70710-1284 70710-1284 Zydus Pharmaceuticals USA Inc. — November 1, 2018

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.